13th February 2008

 

CELLEXUS BIOSYSTEMS PLC

 (“Cellexus” or “the Company”)

 (PLUS Markets: CBIO)

 

Cellexus Biosystems reports the Granting of Fundamental Technology UK Patent

The Board of Cellexus Biosystems plc (PLUS Markets: CBIO), the specialist in the design, manufacture and commercialisation 

of novel disposable technology for growing cells, announces that the Company has been issued with the British 

patent GB2433216 covering the core technology for the CellMaker family of disposable bioreactor and fermentor products.

(1) GB2433216.  Cellexus Biosystems plc. Inventor: Auton, K.A. Cell Culture Vessel.

Commenting on this granting by the UK Patent Office, the inventor of the CellMaker technology, Dr Kevin Auton, commented:  

“Grant of this first patent for the Cellexus technology is an important milestone for Cellexus Biosystems as it provides us with the

protection we require to exploit our position in cell culture and fermentation and validates the novelty of our single-use 

Bioreactor and fermentors.  We now routinely demonstrate that the CellMaker technology is as effective as a traditional 

stirred bioreactor, even for fermentation, which requires high rates of oxygen transfer.  High mass transfer of oxygen is 

achieved without moving parts and is a result of the unique bioreactor geometry.  This patent will be filed in all major 

markets and has already been filed in the US”.   

More information about the core technology surrounding the CellMaker technology and other disposable systems can be can 

be found on the web site:

http://www.cellexusbiosystems.com/index_files/Cellmakerlitedisposablebioreactortechnology2.htm

Further information:

 

Cellexus Biosystems plc:

Dr Kevin Auton

Chief Operations Director

12 Ramsay Court, Hinchingbrooke Business Park
Huntingdon, Cambridgeshire PE29 6FY
United Kingdom

Tel: +44 1480 451 499

kevin.auton@cellexusbiosystems.com

www.cellexusbiosystems.com        

 

Media enquiries:

Bishopsgate Communications Ltd.                                   

Nick Farmer

+44 (0)20 7562 3350

cellexus@bishopsgatecommunications.com

 

 

Trade Press enquiries:     

Jessica Auton

+44 1480 352 821

jessica.auton@cellexusbiosystems.com

Notes to editors:

Cellexus Biosystems sells high performance, single-use, bioreactors to the biopharmaceutical industry.  Our products have proven performance advantages and save our customers time, expense and reduce risk. Biopharmaceuticals are molecules made by cells cultured in vessels called bioreactors.
Reducing the time to market is driving every biopharmaceutical company to adopt single-use technologies.  These are less expensive to buy, faster to adopt and have shorter turnaround times between experiments or batches.

The bioreactor systems we sell are:  the CellMaker Lite2^TM (for bacteria and yeast cells) and the CellMaker PLUS^TM (a highly sophisticated system for mammalian and insect cells, in addition to bacteria and yeast).  The single-use element is a medical-grade bag in which the cells are cultured.  There are two variants of these cell culture bags:  CellexusBag^TM (bacteria and yeast cells) and the HybridBag^TM (bacteria and yeast cells mammalian cells and insect cells).

Our vision is to be a major supplier of single-use technologies to the biopharmaceutical industry, provide cutting-edge technologies and to be recognized as a consistent innovator in our vertical market.  The Company has a wholly owned Subsidiary in the USA.  The majority of our products are purchased by customers in the USA and EU. 

Images of the CellMaker family of products can be downloaded from the Company’s website

http://www.cellexusbiosystems.com/index_files/CellexusBiosystemsMediaResources.htm